Seeking Alpha

Allergan expects EPS growth of 20-25% next year

  • Allergan (AGN) ramps up its propaganda efforts in its battle to stay out the clutches of Valeant (VRX), saying that it expects EPS to increase 20-25% in 2015 and at an annual compound rate of 20% over five years.
  • The company also forecasts "double-digit revenue growth" next year and over the coming five years.
  • Meanwhile, Allergan has received over 500 letters from physician customers, patient advocacy groups and medical associations expressing support for the company following its rejection of Valeant's bid.
  • Physicians have what Allergan describes as "grave concerns" about Valeant's proposal to slash Allergan's R&D expenditure by $1B a year. (PR)
  • Previous coverage
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs